We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
Read MoreHide Full Article
Key Takeaways
{\"0\":\"GSK plans $30B U.S. investment in R&D and supply chain infrastructure over the next five years.\",\"1\":\"A $1.2B biologics flex factory in Pennsylvania will develop respiratory and cancer drugs.\",\"2\":\"New AI and digital upgrades will enhance GSK\'s five U.S. manufacturing sites across four states.\"}
GSK plc (GSK - Free Report) has unveiled a $30 billion investment plan in research and development (R&D) and supply chain infrastructure in the United States, which will be executed over the next five years.
GSK’s latest initiative would include a new $1.2 billion investment in advanced manufacturing facilities and cutting-edge digital and AI technologies to build next-generation biopharma factories and laboratories in the United States. The latest development reflects GSK’s investment in U.S. manufacturing and R&D to expand domestic production as tariff pressures loom under President Donald Trump.
The $1.2 billion investment will include a new biologics flex factory in Pennsylvania aimed at producing best-in-class new medicines for respiratory diseases and various cancer indications. The company will also add new AI and advanced digital technology capabilities at its existing five U.S. manufacturing sites across four states Pennsylvania, North Carolina, Maryland and Montana. In addition, GSK plans to build new drug manufacturing capabilities, improve devices and auto-injectors and strengthen assembly operations.
The new facilities will connect research and manufacturing in the United States and U.K., boosting both countries’ positions as leaders in life sciences.
GSK's Price Performance
Year to date, shares of GSK have rallied 18.4% compared with the industry’s 2.7% rise.
Image Source: Zacks Investment Research
Focus on Ramping Up U.S. Manufacturing
The uncertainty around tariffs and trade production measures has affected economic growth. Previously, President Trump had threatened to impose heavy tariffs, as high as 250%, on pharmaceutical imports, over time. His repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing U.S. pharma companies to shift production back to the country, primarily from Europe and Asia. The U.S. President stated that drugmakers have about one to one and a half years to bring production back to the country before the new tariffs are imposed.
In response to Trump’s tariff threats, several pharma/biotech bigwigs like Eli Lilly (LLY - Free Report) , J&J (JNJ - Free Report) and AstraZeneca (AZN - Free Report) , among others, have already announced plans to ramp up manufacturing in the United States.
Earlier this week, Eli Lilly unveiled a $5 billion plan to build a massive new manufacturing facility in Virginia aimed at creating high-paying manufacturing and construction jobs.
In February, LLY announced plans to bolster its domestic drug production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States, bringing its total domestic manufacturing expansion commitments to over $50 billion since 2020.
In July, AstraZeneca announced a $50 billion investment plan in the United States, including a major manufacturing facility in Virginia, which is to be executed by 2030.
In addition to the Virginia facility, AZN’s broader investment will support the expansion of several key R&D and manufacturing hubs across the United States.
In March 2025, JNJ announced plans to invest more than $55 billion in the United States over the next four years to strengthen manufacturing, R&D and technology in the country.
Image: Bigstock
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
Key Takeaways
GSK plc (GSK - Free Report) has unveiled a $30 billion investment plan in research and development (R&D) and supply chain infrastructure in the United States, which will be executed over the next five years.
GSK’s latest initiative would include a new $1.2 billion investment in advanced manufacturing facilities and cutting-edge digital and AI technologies to build next-generation biopharma factories and laboratories in the United States. The latest development reflects GSK’s investment in U.S. manufacturing and R&D to expand domestic production as tariff pressures loom under President Donald Trump.
The $1.2 billion investment will include a new biologics flex factory in Pennsylvania aimed at producing best-in-class new medicines for respiratory diseases and various cancer indications. The company will also add new AI and advanced digital technology capabilities at its existing five U.S. manufacturing sites across four states Pennsylvania, North Carolina, Maryland and Montana. In addition, GSK plans to build new drug manufacturing capabilities, improve devices and auto-injectors and strengthen assembly operations.
The new facilities will connect research and manufacturing in the United States and U.K., boosting both countries’ positions as leaders in life sciences.
GSK's Price Performance
Year to date, shares of GSK have rallied 18.4% compared with the industry’s 2.7% rise.
Image Source: Zacks Investment Research
Focus on Ramping Up U.S. Manufacturing
The uncertainty around tariffs and trade production measures has affected economic growth. Previously, President Trump had threatened to impose heavy tariffs, as high as 250%, on pharmaceutical imports, over time. His repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing U.S. pharma companies to shift production back to the country, primarily from Europe and Asia. The U.S. President stated that drugmakers have about one to one and a half years to bring production back to the country before the new tariffs are imposed.
In response to Trump’s tariff threats, several pharma/biotech bigwigs like Eli Lilly (LLY - Free Report) , J&J (JNJ - Free Report) and AstraZeneca (AZN - Free Report) , among others, have already announced plans to ramp up manufacturing in the United States.
Earlier this week, Eli Lilly unveiled a $5 billion plan to build a massive new manufacturing facility in Virginia aimed at creating high-paying manufacturing and construction jobs.
In February, LLY announced plans to bolster its domestic drug production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States, bringing its total domestic manufacturing expansion commitments to over $50 billion since 2020.
In July, AstraZeneca announced a $50 billion investment plan in the United States, including a major manufacturing facility in Virginia, which is to be executed by 2030.
In addition to the Virginia facility, AZN’s broader investment will support the expansion of several key R&D and manufacturing hubs across the United States.
In March 2025, JNJ announced plans to invest more than $55 billion in the United States over the next four years to strengthen manufacturing, R&D and technology in the country.
GSK’s Zacks Rank
GSK has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.